Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis.
Saved in:
| Title: | Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. |
|---|---|
| Authors: | Burstein AH; vTv Therapeutics LLC, High Point, NC, USA., Brantley SJ; Nuventra, Inc., Durham, NC, USA., Dunn I; vTv Therapeutics LLC, High Point, NC, USA., Altstiel LD; Formerly vTv Therapeutics LLC, High Point, NC, USA., Schmith V; vTv Therapeutics LLC, High Point, NC, USA. |
| Source: | Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2019 May; Vol. 8 (4), pp. 426-435. Date of Electronic Publication: 2019 Apr 01. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2160-7648 (Electronic) Linking ISSN: 2160763X NLM ISO Abbreviation: Clin Pharmacol Drug Dev Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2160-7648 |
|---|---|
| DOI: | 10.1002/cpdd.689 |
